1. Basic Info

Product Name:	Armodafinil
Synonyms:	R MODAFINIL;Armodafinil;2-[(R)-(Diphenylmethyl)sulfinyl]-acetamide;CEP 10952;CRL 40982;Nuvigil;AcetaMide,2-[(R)-(diphenylMethyl)sulfinyl]-;2-[(R)-(Diphenylmethyl)sulfinyl]-acetamide, CEP 10952, CRL 40982, Nuvigil
CAS:	112111-43-0
MF:	C15H15NO2S
MW:	273.354
EINECS:
Product Categories:	Chiral Reagents;Intermediates & Fine Chemicals;Neurochemicals;Pharmaceuticals;NUVIGIL
Mol File:	112111-43-0.mol

2. Descriptions:

Armodafinil, an α1-adrenoceptor agonist, was launched for the oral treatment of excessive sleepiness associated with narcolepsy, SWSD, and obstructive sleep apnea/hypopnea syndrome (OSA). It is the R-enantiomer of modafinil, which is a previously marketed wake-promoting agent. The key differentiator for armodafinil is its longer pharmacokinetic half-life as compared with the S-enantiomer (10-14 hvs.3-4h). At therapeutic concentrations, armodafinil does not bind to most of the potentially relevant receptors for sleep/wake regulation (e.g., serotonin, dopamine, and adenosine receptors) or transporters of neurotransmitters or enzymes involved in sleep/wake regulation (e.g., serotonin, norepinephrine, and phosphodiesterase VI transporters). Both armodafinil and modafinil block dopamine reuptake by binding to the dopamine transporter and increasing dopamine concentrations in certain regions of the brain. However, dopamine receptor antagonists (e.g., haloperidol) and dopamine synthesis inhibitors (e.g., α-methyl-p-tyrosine) do not block modafinil’s action.
In addition to its wake-promoting effects and ability to increase locomotor activity in animals, modafinil produces psychoactive and euphoric effects, alterations in mood, perception, thinking, and feelings typical of other CNS stimulants in humans. Modafinil was also partially discriminated as stimulant-like. However, the potential for abuse and dependency appears to be lower for modafinil than amphetamine-like stimulants.The most common adverse events associated with armodafinil included headache, nausea, dizziness, and insomnia.

3. Applications:

Armoda-finil is currently FDA-approved to treat excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy, and shift work disorder. It is commonly used off-label to treat attention deficit hyperactivity disorder, chronic fatigue syndrome, and major depressive disorder. It has been shown to improve vigilance in air traffic controllers.

Armodafinil is used for:
Improving wakefulness in patients with excessive sleepiness from sleep apnea, narcolepsy, or shift work disorder. It may also be used for other conditions as determined by your doctor.
Armoda-finil is a wakefulness-promoting agent. Exactly how it works is not known. Armoda-finil affects certain chemicals in the brain that may affect sleep.

Sleep disorders
Armoda-finil is approved by the U.S. FDA for the treatment of narcolepsy and shift work sleep disorder, and as an adjuvant therapy for obstructive sleep apnea.For narcolepsy and obstructive sleep apnea, armoda-finil is taken as a once daily 150 mg or 250 mg dose in the morning. For shift work sleep disorder, 150 mg of armoda-finil are taken one hour prior to starting work. Slow dose titration is needed to mitigate some side effects.

Armodafinil Dosage

The difference in armodafinil dosage versus modafinil is not huge, but it is significant. The recommended dosage (for medical patients suffering certain diseases) is 150 mg one time in the morning. This is compared to the 200 mg that users take for modafinil.

other product : 

About us:

we, Yihan Industrial Co., Ltd from china are specilized in steroids powder , semi-finished liquids , peptides , Sarm powder,HGH,HCG,Finished Liquid and other pharmaceutical materials for many years .

If you have any further questions or need a sample,Please do not hesitate to contact me.Thank you!